ANTI-TUMOR ACTIONS OF CYTOTOXIC DRUGS PLUS MUSCARINIC AGONISTS ON HUMAN TRIPLE NEGATIVE BREAST CANCER CELLS

SANCHEZ, Y; ALEJANDRO ESPAÑOL; SALEM , AGUSTINA; MARÍA E. SALES

Mar del Plata

Congreso; LXIII REUNION ANUAL DE LA SOCIEDAD ARGENTINA DE INVESTIGACION CLINICA; 2018

SAIC SAI SAFIS

The administration of low doses of cytotoxic drugs alone or combinedwith repurposing drugs scheduled with short inter-dose intervalsis called metronomic therapy (MT). MT is a new strategy in cancertreatment, since it exhibits high effectiveness and low incidenceof side effects. We previously demonstrated that the activation ofmuscarinic receptors (M) can modulate breast cancer cell viability.Triple negative (TN) breast tumors are highly aggressive, and theeffectiveness of pharmacological treatment is low probably due tothe absence of a specific target. Here, we analyzed the effect ofa combination of subthreshold concentrations of a muscarinic agonist,carbachol (CARB) or arecaidine propargyl ester (APE) (nonselectiveor selective for M2 subtype respectively) with paclitaxel(PX) or doxorubicin (DX), two cytotoxic drugs used in breast cancertreatment, on MDA-MB231 or MDA-MB468 TN tumor-derivedcell lines. By MTT assay we observed on MDA-MB231 cells thatthe combination of PX+CARB or PX+APE reduced cell viability(23.9±2.5%; 23.5±7.1% respect to control; p